Dogwood Therapeutics (NASDAQ:DWTX) Given Buy Rating at HC Wainwright

Dogwood Therapeutics (NASDAQ:DWTX)‘s stock had its “buy” rating reaffirmed by research analysts at HC Wainwright in a research note issued to investors on Friday,Benzinga reports. They currently have a $12.00 price objective on the stock. HC Wainwright’s price target indicates a potential upside of 313.79% from the stock’s previous close.

A number of other research firms also recently weighed in on DWTX. Weiss Ratings restated a “sell (e+)” rating on shares of Dogwood Therapeutics in a research report on Monday, December 22nd. Wall Street Zen cut Dogwood Therapeutics to a “strong sell” rating in a report on Saturday, December 13th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average price target of $12.00.

Dogwood Therapeutics Trading Down 5.5%

DWTX stock opened at $2.90 on Friday. Dogwood Therapeutics has a 1-year low of $2.60 and a 1-year high of $15.00. The stock has a market cap of $6.64 million, a price-to-earnings ratio of -0.12 and a beta of 1.90. The company’s 50 day moving average is $4.67 and its 200 day moving average is $5.13.

Dogwood Therapeutics (NASDAQ:DWTX) last released its quarterly earnings results on Thursday, November 6th. The company reported ($8.20) EPS for the quarter, missing analysts’ consensus estimates of ($1.23) by ($6.97). As a group, sell-side analysts forecast that Dogwood Therapeutics will post -6.43 EPS for the current fiscal year.

About Dogwood Therapeutics

Dogwood Therapeutics is a clinical‐stage biotechnology company dedicated to the discovery and development of novel biologic therapies aimed at reducing fibrosis and promoting tissue repair in cardiovascular and other fibrotic diseases. The company leverages a proprietary Discovery Engine that integrates high‐throughput screening, functional genomics and protein engineering to identify and optimize candidate proteins and antibodies with therapeutic potential.

Dogwood’s lead programs are focused on preventing adverse cardiac remodeling following myocardial injury and improving outcomes in heart failure patients.